Accessibility Menu
Qsam Biosciences logo

Qsam Biosciences(OTC) QSAM

This security has been delisted. This page is retained for historical reference.

Qsam Biosciences last closing stock price
MetricPriceDate
Last closeUSD 8.302024-05-02
Qsam Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99.95%USD 16,180.002024-04-25
1 month-99.94%USD 15,000.002024-03-26
3 month-99.92%USD 10,700.002024-02-02
Year to date-99.93%USD 12,200.002023-12-29
1 year-99.93%USD 11,800.002023-05-03
3 year-99.97%USD 31,200.002021-04-28
5 year-100%USD 197,100.002017-12-06
Since inception-98.37%USD 1,020,000.002015-11-19

QSAM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

QSAM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

1617.91%

Return on Capital

-579.91%

Return on Assets

-257.62%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$549.00K

Operating Income

-$3.94M

EBITDA

-$3.74M

Operating Cash Flow

-$2.85M

Capital Expenditure

$0.00

Free Cash Flow

-$2.85M

Cash & ST Invst.

$1.39M

Total Debt

$7.50K

Qsam Biosciences Performance Analysis

Qsam Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Qsam Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Q42023-12-31N/A
Qsam Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -34,241.60N/A
20222022-12-31USD -6,894.82-79.9%
20232023-12-31USD -3,202.54-53.6%
Qsam Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31-2.3%
Q22023-06-3052.2%
Q32023-09-3016.3%
Q42023-12-3163.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$1.10M

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

4

N/A

Net Income

-$484.00K

+58.8%

EBITDA

-$436.19K

+61.1%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$1.39M

+515.4%

Total Debt

$7.50K

-98.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$7.50K

-98.3%

Return on Assets

-2.58%

N/A

Return on Invested Capital

-5.86%

N/A

Free Cash Flow

-$1.16M

-0.8%

Operating Cash Flow

-$1.16M

-0.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTBOCantabio Pharmaceuticals, Inc.
$1.01+0.00%
RTSLRapid Therapeutic Science Laboratories, Inc.
$0.00+0.00%
CBDHFHempfusion Wellness Inc.
$0.00+0.00%
NMMCFNMC Health plc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.